Skip to content
ADPTAdaptive Biotechnologies Corp

Earnings

When Adaptive Biotechnologies Corp reports, what it reported each quarter, and how the stock took the results.

34 quarters. Jun 30, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 4, after the close

Thu, Feb 4, 2027in 78 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 12 – Mar 4

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$71.68M
Revenue, change from a year earlier: Q3 2026 −10.7%, Q2 2026 +21.5%, Q1 2026 +35.1%, Q4 2025 +51.0%
Net income
-$13.58M
Net income, change from a year earlier: Q3 2026 −69.9%, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 −66.7%, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$83.90M−10.7% vs Q3 2025

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release+0.2%by the close of Nov 5
    Revenue
    $83.90M
    −10.7%
    Net income
    $2.88M
    −69.9%
    EPS
    $0.02
    −66.7%
    Revenue was $83.9 million for the quarter ended September 30, 2026, representing an 11% decrease from the third quarter in the prior year.
  2. Q2 2026Jul 29, 2026, after the closeThe release+7.0%by the close of Jul 30
    Revenue
    $71.55M
    +21.5%
    Net income
    -$39.79M
    N/M
    EPS
    -$0.25
    N/M
  3. Q1 2026May 5, 2026, after the closeThe release+4.6%by the close of May 6
    Revenue
    $70.87M
    +35.1%
    Net income
    -$20.03M
    N/M
    EPS
    -$0.13
    N/M
  4. Q4 2025Feb 5, 2026, after the closeThe release4.2%by the close of Feb 6
    Revenue
    $71.68M
    +51.0%
    Net income
    -$13.58M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q$83.90M−10.7%$0.02+0.2%
Q2 2026Jun 30, 2026Jul 29, 2026 · after-hoursAug 4, 202635 d10-Q$71.55M+21.5%-$0.25+7.0%
Q1 2026Mar 31, 2026May 5, 2026 · after-hoursMay 5, 202635 d10-Q$70.87M+35.1%-$0.13+4.6%
FY 2025
Q4 2025derivedDec 31, 2025Feb 5, 2026 · after-hoursFeb 26, 202657 d10-K$71.68M+51.0%—4.2%
Q3 2025Sep 30, 2025Nov 5, 2025 · after-hoursNov 5, 202536 d10-Q$93.97M+102.4%$0.0611.5%
Q2 2025Jun 30, 2025Aug 5, 2025 · after-hoursAug 5, 202536 d10-Q$58.88M+36.3%-$0.17+6.1%
Q1 2025Mar 31, 2025May 1, 2025 · after-hoursMay 1, 202531 d10-Q$52.44M+25.2%-$0.20+34.0%
FY 2024
Q4 2024derivedDec 31, 2024Feb 11, 2025 · after-hoursMar 3, 202562 d10-K$47.46M+3.7%—3.2%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$46.44M+22.5%-$0.22+3.6%
Q2 2024Jun 30, 2024Aug 1, 2024 · after-hoursAug 1, 202432 d10-Q$43.19M−11.7%-$0.315.5%
Q1 2024Mar 31, 2024May 7, 2024 · after-hoursMay 7, 202437 d10-Q$41.87M+11.2%-$0.33+14.5%
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026447411
10-QAug 4, 2026332940
10-QMay 5, 2026206546
10-KFeb 26, 2026076902
10-QNov 5, 2025267061
10-QAug 5, 2025103120
10-QMay 1, 2025061897
10-KMar 3, 2025030913
10-QNov 7, 2024123423
10-QAug 1, 2024089342

Provenance

ProvenanceData status and checks

Adaptive Biotechnologies Corp · CIK 1478320 · Engraved from SEC EDGAR